By Adria Calatayud 
 

GlaxoSmithKline PLC (GSK.LN) and Innoviva Inc. (INVA) said Thursday that their Trelegy Ellipta inhaler, which treats patients living with uncontrolled asthma, met the primary endpoint in a phase 3 study.

The pharmaceutical companies said the study showed a statistically significant improvement in lung function at 24 weeks of once-daily treatment with Trelegy Ellipta compared with other medication.

However, the drug didn't achieve a statistically significant reduction in the annualized rate of asthma exacerbations, which was the secondary endpoint of the trial, the companies said.

 

Write to Adria Calatayud at adria.calatayudvaello@dowjones.com

 

(END) Dow Jones Newswires

May 02, 2019 12:44 ET (16:44 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Grafico Azioni Gsk (LSE:GSK)
Storico
Da Feb 2024 a Mar 2024 Clicca qui per i Grafici di Gsk
Grafico Azioni Gsk (LSE:GSK)
Storico
Da Mar 2023 a Mar 2024 Clicca qui per i Grafici di Gsk